CBS 2019
CBSMD教育中心
中 文

Percutaneous LAA Occlusion

Abstract

Recommended Article

Transseptal puncture versus patent foramen ovale or atrial septal defect access for left atrial appendage closure 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
|<< 1 2 3 4 5 6 >>|

Original Research12 October 2021

JOURNAL：Ann Intern Med. Article Link

Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study

AB Ingason, JP Hreinsson, ES Björnsson et al. Keywords: rivaroxaban vs DOAC; AF; gastrointestinal bleeding

ABSTRACT

BACKGROUND - Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs) and warfarin have been extensively compared. However, population-based studies comparing GIB rates among different DOACs are limited.


OBJECTIVE - To compare rates of GIB among apixaban, dabigatran, and rivaroxaban.


DESIGN - Nationwide population-based cohort study.


SETTING - Landspítali–The National University Hospital of Iceland and the 4 regional hospitals in Iceland.


PATIENTS - New users of apixaban, dabigatran, and rivaroxaban from 2014 to 2019.


MEASUREMENTS - Rates of GIB were compared using inverse probability weighting, Kaplan–Meier survival estimates, and Cox regression.


RESULTS - In total, 2157 patients receiving apixaban, 494 patients receiving dabigatran, and 3217 patients receiving rivaroxaban were compared. For all patients, rivaroxaban had higher overall rates of GIB (3.2 vs. 2.5 events per 100 person-years; hazard ratio [HR], 1.42 [95% CI, 1.04 to 1.93]) and major GIB (1.9 vs. 1.4 events per 100 person-years; HR, 1.50 [CI, 1.00 to 2.24]) compared with apixaban. Rivaroxaban also had higher GIB rates than dabigatran, with similar point estimates, although the CIs were wider and included the possibility of a null effect. When only patients with atrial fibrillation were included, rivaroxaban was associated with higher rates of overall GIB than apixaban (HR, 1.40 [CI, 1.01 to 1.94]) or dabigatran (HR, 2.04 [CI, 1.17 to 3.55]). Dabigatran was associated with lower rates of upper GIB than rivaroxaban in both analyses.


LIMITATIONS - Unmeasured confounding and small subgroup analyses.


CONCLUSION - Rivaroxaban was associated with higher GIB rates than apixaban and dabigatran regardless of treatment indication.


PRIMARY FUNDING SOURCE - Icelandic Centre for Research and Landspítali–The National University Hospital of Iceland.


>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top